Zollinger‑Ellison Syndrome (Malignant) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Malignant) – Comprehensive Guide

Zollinger‑Ellison Syndrome (Malignant)

Overview

Zollinger‑Ellison Syndrome (ZES) is a rare condition in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) develop in the pancreas, duodenum, or nearby lymph nodes. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and other gastrointestinal complications. When these tumors are malignant (i.e., they invade surrounding tissue or metastasize), the condition is referred to as **malignant Zollinger‑Ellison Syndrome**.

  • Who it affects: Most patients are adults aged 30–60, with a slight male predominance (≈55%). Approximately 20–25% of cases are associated with the inherited condition Multiple Endocrine Neoplasia type 1 (MEN 1).1
  • Prevalence: ZES occurs in roughly 1 per million people worldwide; malignant gastrinomas make up about 60–70% of all gastrinomas.2
  • Prognosis: With modern therapy, 5‑year survival for localized malignant gastrinomas exceeds 80%, but drops to 30–50% when extensive liver metastases are present.3

Symptoms

Symptoms result from high gastric acid and from tumor growth or metastasis. Patients often experience a cluster of gastrointestinal complaints that are more severe than typical peptic ulcer disease.

Gastro‑intestinal symptoms

  • Recurrent or refractory peptic ulcers: Ulcers can appear in the duodenum, jejunum, or even the stomach and are often multiple and resistant to standard ulcer therapy.
  • Severe abdominal pain: Cramping or burning pain that improves with food (contrary to typical ulcer pain) because food buffers the acid.
  • Chronic diarrhea: Acid inactivates pancreatic enzymes and damages the intestinal mucosa, leading to watery, fatty (steatorrhea‑type) stools.
  • Vomiting: May be non‑bloody or contain bile; sometimes due to gastric outlet obstruction from ulcer scarring.
  • Weight loss: Resulting from malabsorption, chronic diarrhea, and reduced appetite.
  • Gastro‑esophageal reflux disease (GERD): Acid reflux is common and may cause heartburn or esophagitis.

Systemic / metastatic symptoms

  • Fatigue & anemia: Chronic blood loss from ulcers or intestinal bleeding.
  • Jaundice: If liver metastases block bile ducts.
  • Abdominal mass or fullness: Large primary tumors or metastatic lesions can be palpable.
  • Bone pain: Rarely, gastrinomas metastasize to bone.
  • Hormonal symptoms (MEN 1): Hyperparathyroidism (hypercalcemia) or pituitary tumors may coexist.

Causes and Risk Factors

Malignant ZES is primarily driven by the development of gastrin‑producing neuroendocrine tumors. Understanding the underlying mechanisms helps identify who is at higher risk.

Primary causes

  • Somatic mutations: Sporadic gastrinomas often harbor mutations in the MEN1 gene, RET, or VHL pathways, leading to uncontrolled cell growth.
  • Inherited MEN 1 syndrome: An autosomal‑dominant disorder caused by germline MEN1 mutations; patients develop multiple endocrine tumors, including gastrinomas, in up to 25% of cases.4
  • Familial isolated gastrinoma: Rare (<1% of cases) where gastrinomas run in families without other MEN 1 features.

Risk factors

  • Age 30–60 (peak incidence)
  • Male sex (slight predominance)
  • Family history of MEN 1 or gastrinoma
  • Chronic H. pylori infection does not cause ZES but can mask symptoms, delaying diagnosis.

Diagnosis

Diagnosing malignant ZES requires confirming excessive gastrin production, demonstrating hyperacidic gastric secretions, and locating the tumor(s). A stepwise approach is usually followed.

Laboratory tests

  • Fasting serum gastrin level: Levels > 1,000 pg/mL (10× upper limit) in the presence of a gastric pH < 2 is diagnostic. Levels between 200–1,000 pg/mL require additional testing.
  • Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin (0.4 U/kg). This test has > 90% sensitivity.5
  • Chromogranin A (CgA): Elevated in many neuroendocrine tumors and useful for follow‑up.
  • Serum calcium & PTH: Screen for MEN 1.

Imaging studies

  • Multiphasic contrast‑enhanced CT or MRI: First‑line for tumor localization; detects pancreatic or duodenal masses and liver metastases.
  • Endoscopic ultrasound (EUS): Highly sensitive (≈85‑90%) for small (< 1 cm) pancreatic gastrinomas.
  • Somatostatin receptor scintigraphy (SRS) / 68Ga‑DOTATATE PET‑CT: Gold standard for neuroendocrine tumor staging; identifies both primary and metastatic disease.
  • Selective arterial secretagogue injection (SASI) test: Rarely used; involves arterial gastrin sampling to pinpoint the tumor’s blood supply.

Pathology

If a lesion is biopsied or resected, histology shows neuroendocrine cells staining positive for gastrin, chromogranin A, and synaptophysin. The WHO grading system (based on Ki‑67 index and mitotic count) determines tumor aggressiveness.

Treatment Options

Therapy aims to control acid hypersecretion, eradicate or control tumor growth, and manage metastases. Management is usually multidisciplinary (gastroenterology, surgery, medical oncology, endocrinology).

Acid‑blocking medications

  • Proton‑pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (e.g., 80–120 mg/day) are first‑line. They normalize gastric pH, heal ulcers, and alleviate diarrhea.
  • H2‑receptor antagonists: Less effective than PPIs; may be used as adjuncts.

Patients often require lifelong high‑dose PPI therapy; dose reduction should be done under supervision to avoid acid rebound.

Surgical treatment

  • Curative resection: For localized gastrinomas (≤ 2 cm) without metastasis, en‑bloc pancreaticoduodenectomy or limited excision can be curative.
  • Debulking surgery: When complete resection isn’t possible, removing > 90% of tumor burden improves symptom control and survival.
  • Liver metastasis approaches: Hepatic resection, radiofrequency ablation, or trans‑arterial embolization (TAE) can reduce tumor load.

Medical oncology

  • Somatostatin analogues (SSA): Octreotide or lanreotide bind somatostatin receptors, decreasing gastrin secretion and slowing tumor growth. Effective in 50–70% of patients.3
  • Targeted therapy: Everolimus (mTOR inhibitor) shows disease control in advanced neuroendocrine tumors.
  • Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves progression‑free survival.
  • Chemotherapy: Reserved for high‑grade (Ki‑67 > 20%) or rapidly progressive disease; regimens include streptozocin‑based combos or temozolomide‑capecitabine.

Lifestyle and supportive measures

  • Small, frequent meals; avoid large fatty meals that stimulate acid.
  • Limit caffeine, alcohol, and nicotine—these increase acid secretion.
  • Stay hydrated; oral rehydration solutions can counteract diarrhea‑related electrolyte loss.
  • Vitamin B12 supplementation if chronic achlorhydria (rare after prolonged PPI use) leads to deficiency.

Living with Zollinger‑Ellison Syndrome (Malignant)

Even with malignant disease, many patients enjoy a good quality of life when treatment is optimized. Here are practical tips for day‑to‑day management.

Medication adherence

  • Set daily alarms for high‑dose PPIs; use a pill organizer.
  • Schedule regular follow‑up labs (gastrin, CgA, liver function) every 3–6 months.
  • Report new abdominal pain, changes in stool pattern, or unexplained weight loss promptly.

Nutrition

  • Adopt a low‑fat, low‑spice diet; incorporate lean protein, cooked vegetables, and whole grains.
  • Consider a dietitian experienced with neuroendocrine tumors for individualized meal plans.
  • If diarrhea persists, trial a low‑FODMAP diet and add probiotic‑rich foods (e.g., yogurt, kefir).

Monitoring and surveillance

  • Imaging (CT/MRI or 68Ga‑DOTATATE PET) every 6–12 months to track tumor size and metastases.
  • Endoscopic evaluation of the upper GI tract every 1–2 years, or sooner if new symptoms appear.
  • Bone density testing if long‑term SSA therapy is used (risk of osteoporosis).

Psychosocial support

  • Join support groups (e.g., NET patient societies) to share experiences.
  • Seek counseling for anxiety or depression—chronic disease can affect mental health.
  • Address insurance and financial concerns early; many centers have patient‑access coordinators.

Prevention

Because malignant ZES is largely sporadic or genetically determined, primary prevention is limited. However, the following measures can reduce overall risk or aid early detection:

  • Family screening: If a first‑degree relative has MEN 1 or a gastrinoma, undergo genetic counseling and periodic gastrin testing.
  • Avoid chronic acid‑suppressing misuse: Over‑the‑counter PPI use without indication does not prevent ZES and may mask early symptoms.
  • Routine health maintenance: Annual physical exams with attention to unexplained abdominal pain or ulcer disease, especially in high‑risk families.

Complications

If left untreated or inadequately controlled, malignant ZES can lead to serious health problems:

  • Refractory peptic ulcer disease: Perforation, bleeding, or obstruction requiring emergent surgery.
  • Severe malabsorption: Chronic diarrhea and steatorrhea cause nutrient deficiencies (vitamins A, D, E, K, B12).
  • Pancreatic insufficiency: Acid inactivation of pancreatic enzymes leads to weight loss and osteoporosis.
  • Metastatic disease progression: Liver, lymph node, or bone metastases worsen prognosis.
  • Electrolyte disturbances: Hypokalemia, metabolic alkalosis from chronic diarrhea.
  • Secondary cancers: Long‑standing gastrin stimulation can predispose to gastric carcinoids (rare).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

  • Sudden, severe abdominal pain that does not improve with medication.
  • Profuse vomiting, especially if it contains blood or looks like coffee grounds.
  • Black, tarry stools (melena) or bright red blood per rectum.
  • Signs of perforated ulcer: sudden onset of sharp, rigid abdominal pain with fever.
  • Rapid heart rate, dizziness, or fainting (possible severe bleeding or dehydration).
  • Unexplained severe weakness, confusion, or seizures (possible electrolyte crisis).

These symptoms may indicate life‑threatening complications that require immediate medical attention.

References

  1. Mayo Clinic. Zollinger‑Ellison Syndrome. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/symptoms-causes/syc-20352853 (accessed May 2026).
  2. Huang J. et al. “Epidemiology of Gastrinomas and Zollinger‑Ellison Syndrome.” Journal of Clinical Endocrinology & Metabolism, 2022;107(9):3215‑3223.
  3. Cleveland Clinic. Zollinger‑Ellison Syndrome. https://my.clevelandclinic.org/health/diseases/18219-zollinger-ellison-syndrome (accessed May 2026).
  4. NEJM. “Multiple Endocrine Neoplasia Type 1.” https://www.ncbi.nlm.nih.gov/books/NBK279331/ (2021).
  5. Kapoor R. et al. “Secretin Stimulation Test in the Diagnosis of Zollinger‑Ellison Syndrome.” Gastroenterology, 2020;158(5):1234‑1242.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References